Publication Name	World Journal of Gastroenterology
Manuscript ID	85347
Country	China

Received	2023-04-23 13:57
Peer-Review Started	2023-04-23 13:59
To Make the First Decision
Return for Revision	2023-07-09 07:45
Revised	2023-07-19 13:59
Second Decision	2023-08-14 02:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-08-15 09:25
Articles in Press	2023-08-15 09:25
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-08-17 23:53
Typeset the Manuscript	2023-08-31 00:19
Publish the Manuscript Online	2023-09-08 09:01

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
Manuscript Source	Invited Manuscript
All Author List	Yong Liu
ORCID	Author(s) ORCID Number Yong Liu http://orcid.org/0000-0002-4048-5837
Funding Agency and Grant Number
Corresponding Author	Yong Liu, Doctor, MD, Chief Doctor, Surgeon, Surgical Oncologist, Department of Thoracic Surgery, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26 Shengli Street, Wuhan 430011, Hubei Province, China. liuyong7575@163.com
Key Words	Esophageal squamous cell carcinoma; Immune checkpoint inhibitors; Immunotherapy; Neoadjuvant; Randomized clinical trial
Core Tip	Esophageal cancer ranks among the most prevalent malignant tumors affecting the digestive tract. In locally advanced esophageal squamous cell carcinoma (ESCC), the mainstay of treatment involves neoadjuvant therapy in conjunction with surgical resection. Notably, immunotherapy has achieved significant breakthroughs in the 2nd and 1st-line treatment of advanced or metastatic ESCC. This review focuses on the current landscape of perioperative immunotherapy for resectable ESCC and discusses promising biomarkers and future perspectives.
Publish Date	2023-09-08 09:01
Citation	Liu Y. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future. World J Gastroenterol 2023; 29(34): 5020-5037
URL	https://www.wjgnet.com/1007-9327/full/v29/i34/5020.htm
DOI	https://dx.doi.org/10.3748/wjg.v29.i34.5020

Full Article (PDF)	WJG-29-5020-with-cover.pdf
Full Article (Word)	WJG-29-5020.docx
Manuscript File	85347_Auto_Edited-JLW_WangTQ.docx
Answering Reviewers	85347-Answering reviewers.pdf
Audio Core Tip	85347-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	85347-Conflict-of-interest statement.pdf
Copyright License Agreement	85347-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	85347-Language certificate.pdf
Peer-review Report	85347-Peer-review(s).pdf
Scientific Misconduct Check	85347-Bing-Yan JP-2.png
Scientific Editor Work List	85347-Scientific editor work list.pdf